This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Vitrakvi (larotrectinib)
General Description:
Vitrakvi (larotrectinib) is an oral targeted therapy used to treat patients with solid tumors that harbor an NTRK gene fusion, without a known acquired resistance mutation. It is indicated for metastatic tumors, cases where surgery would cause severe morbidity, or when no satisfactory alternative treatments are available, including tumors that have progressed after prior therapy.
Vitrakvi works by blocking the activity of the abnormal NTRK proteins that drive cancer growth. It is administered orally as capsules or as an oral solution, with dosage and treatment schedules determined by a qualified healthcare professional.
Getting Vitrakvi (larotrectinib) in India
Vitrakvi is approved by multiple international regulatory agencies, including the FDA (U.S.), EMA (Europe), Health Canada, and PMDA (Japan). While it may not yet be commercially available in India, patients can access it legally through a Named Patient Program (NPP) under the supervision of a licensed physician.
MitoGENE assists Indian patients in obtaining Vitrakvi safely and efficiently, managing all regulatory approvals, import permits, and logistics to ensure a compliant and secure process.
Disease Indication:
• Solid Tumors / NTRK-positive tumors
Manufacturer:
Bayer
Usage:
Oral Capsules or Oral Solution
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA)
Available Dosage Form & Package:
• 100 mg capsules, 56 capsules per pack
• Oral solution, 20 mg/mL (100 mL)
Shipping:
Room Temperature Shipping
Vitrakvi is shipped under controlled room temperature conditions (15–25°C) to maintain stability and effectiveness. Standard shipping procedures ensure the medication remains safe and uncompromised during transit.
